Shots:

• LG Chem will receive $95.5M for the China rights incl. $10M up front, milestones along with royalties
• Innovent to get an exclusive right to develop & commercialize Tigulixostat in China for the chronic management of hyperuricemia in patients with gout disease. The product is expected to be available in the market shortly
• The P-II study (CLUE Study) results from 156 gout patients showed that the patients treated with Tigulixostat (50/100/200mg) achieved sUA <5 mg/dL (47%/45%/62%) vs 23% with Febuxostat & 3% with PBO; 59%/63%/78% vs 54% & 3% in sUA < 6mg/dL @3mos., sUA-lowering effects across all dose levels & sUA levels were well maintained throughout the study period & showed a favorable safety profile

Ref: PRNewswire | Image: Innovent